Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
PLoS Pathog ; 18(7): e1010618, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35789343

RESUMEN

The novel coronavirus SARS-CoV-2 emerged in late 2019, rapidly reached pandemic status, and has maintained global ubiquity through the emergence of variants of concern. Efforts to develop animal models have mostly fallen short of recapitulating severe disease, diminishing their utility for research focusing on severe disease pathogenesis and life-saving medical countermeasures. We tested whether route of experimental infection substantially changes COVID-19 disease characteristics in two species of nonhuman primates (Macaca mulatta; rhesus macaques; RM, Chlorocebus atheiops; African green monkeys; AGM). Species-specific cohorts were experimentally infected with SARS-CoV-2 by either direct mucosal (intratracheal + intranasal) instillation or small particle aerosol in route-discrete subcohorts. Both species demonstrated analogous viral loads in all compartments by either exposure route although the magnitude and duration of viral loading was marginally greater in AGMs than RMs. Clinical onset was nearly immediate (+1dpi) in the mucosal exposure cohort whereas clinical signs and cytokine responses in aerosol exposure animals began +7dpi. Pathologies conserved in both species and both exposure modalities include pulmonary myeloid cell influx, development of pleuritis, and extended lack of regenerative capacity in the pulmonary compartment. Demonstration of conserved pulmonary pathology regardless of species and exposure route expands our understanding of how SARS-CoV-2 infection may lead to ARDS and/or functional lung damage and demonstrates the near clinical response of the nonhuman primate model for anti-fibrotic therapeutic evaluation studies.


Asunto(s)
COVID-19 , Aerosoles , Animales , Chlorocebus aethiops , Modelos Animales de Enfermedad , Humanos , Pulmón/patología , Macaca mulatta , SARS-CoV-2
2.
Proc Natl Acad Sci U S A ; 118(8)2021 02 23.
Artículo en Inglés | MEDLINE | ID: mdl-33563754

RESUMEN

COVID-19 transmits by droplets generated from surfaces of airway mucus during processes of respiration within hosts infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. We studied respiratory droplet generation and exhalation in human and nonhuman primate subjects with and without COVID-19 infection to explore whether SARS-CoV-2 infection, and other changes in physiological state, translate into observable evolution of numbers and sizes of exhaled respiratory droplets in healthy and diseased subjects. In our observational cohort study of the exhaled breath particles of 194 healthy human subjects, and in our experimental infection study of eight nonhuman primates infected, by aerosol, with SARS-CoV-2, we found that exhaled aerosol particles vary between subjects by three orders of magnitude, with exhaled respiratory droplet number increasing with degree of COVID-19 infection and elevated BMI-years. We observed that 18% of human subjects (35) accounted for 80% of the exhaled bioaerosol of the group (194), reflecting a superspreader distribution of bioaerosol analogous to a classical 20:80 superspreader of infection distribution. These findings suggest that quantitative assessment and control of exhaled aerosol may be critical to slowing the airborne spread of COVID-19 in the absence of an effective and widely disseminated vaccine.


Asunto(s)
COVID-19/fisiopatología , COVID-19/transmisión , Espiración/fisiología , Obesidad/fisiopatología , Aerosoles , Factores de Edad , Animales , Índice de Masa Corporal , COVID-19/epidemiología , COVID-19/virología , Estudios de Cohortes , Humanos , Moco/química , Moco/virología , Obesidad/epidemiología , Obesidad/virología , Tamaño de la Partícula , Primates , Sistema Respiratorio/metabolismo , SARS-CoV-2/aislamiento & purificación , Carga Viral
3.
J Med Primatol ; 52(2): 131-134, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36377612

RESUMEN

Increases of soluble urokinase plasminogen activator receptor (suPAR) were measured in both urine and plasma of a Chlorocebus aethiops (African green monkey; AGM) mucosal infected with SARS-CoV-2. The data indicate that elevated suPAR may be associated with renal dysfunction and pathology in the context of COVID-19.


Asunto(s)
COVID-19 , Enfermedades Renales , Animales , Chlorocebus aethiops , COVID-19/complicaciones , Receptores del Activador de Plasminógeno Tipo Uroquinasa , SARS-CoV-2 , Biomarcadores
4.
Artículo en Inglés | MEDLINE | ID: mdl-30782986

RESUMEN

Staphylococcal enterotoxin B (SEB) is a protein exotoxin found on the cell surface of Staphylococcus aureus that is the source for multiple pathologies in humans. When purified and concentrated in aerosol form, SEB can cause an acute and often fatal intoxication and thus is considered a biological threat agent. There are currently no vaccines or treatments approved for human use. Studies with rodent models of SEB intoxication show that antibody therapy may be a promising treatment strategy; however, many have used antibodies only prophylactically or well before any clinical signs of intoxication are apparent. We assessed and compared the protective efficacies of two monoclonal antibodies, Ig121 and c19F1, when administered after aerosol exposure in a uniformly lethal nonhuman primate model of SEB intoxication. Rhesus macaques were challenged using small-particle aerosols of SEB and then were infused intravenously with a single dose of either Ig121 or c19F1 (10 mg/kg of body weight) at either 0.5, 2, or 4 h postexposure. Onset of clinical signs and hematological and cytokine response in untreated controls confirmed the acute onset and potency of the toxin used in the challenge. All animals administered either Ig121 or c19F1 survived SEB challenge, whereas the untreated controls succumbed to SEB intoxication 30 to 48 h postexposure. These results represent the successful therapeutic in vivo protection by two investigational drugs against SEB in a severe nonhuman primate disease model and punctuate the therapeutic value of monoclonal antibodies when faced with treatment options for SEB-induced toxicity in a postexposure setting.


Asunto(s)
Aerosoles/toxicidad , Anticuerpos Monoclonales/uso terapéutico , Enterotoxinas/toxicidad , Animales , Ensayo de Inmunoadsorción Enzimática , Macaca mulatta
5.
J Med Primatol ; 47(1): 75-77, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-28573738

RESUMEN

Animals were experimentally infected with Brucella melitensis via aerosol. B. melitensis was cultured from the saliva and vaginal vault of infected animals, corresponding to bacterial dissemination in other target tissues. This is the first report of bacterial dissemination to these mucosal surfaces in a non-human primate model of brucellosis.


Asunto(s)
Brucella melitensis/fisiología , Brucelosis/microbiología , Membrana Mucosa/microbiología , Saliva/microbiología , Vagina/microbiología , Aerosoles/administración & dosificación , Animales , Brucelosis/etiología , Femenino , Macaca mulatta , Masculino
6.
Proc Natl Acad Sci U S A ; 112(12): 3782-7, 2015 Mar 24.
Artículo en Inglés | MEDLINE | ID: mdl-25775591

RESUMEN

Ricin toxin (RT) is the second most lethal toxin known; it has been designated by the CDC as a select agent. RT is made by the castor bean plant; an estimated 50,000 tons of RT are produced annually as a by-product of castor oil. RT has two subunits, a ribotoxic A chain (RTA) and galactose-binding B chain (RTB). RT binds to all mammalian cells and once internalized, a single RTA catalytically inactivates all of the ribosomes in a cell. Administered as an aerosol, RT causes rapid lung damage and fibrosis followed by death. There are no Food and Drug Administration-approved vaccines and treatments are only effective in the first few hours after exposure. We have developed a recombinant RTA vaccine that has two mutations V76M/Y80A (RiVax). The protein is expressed in Escherichia coli and is nontoxic and immunogenic in mice, rabbits, and humans. When vaccinated mice are challenged with injected, aerosolized, or orally administered (gavaged) RT, they are completely protected. We have now developed a thermostable, aluminum-adjuvant-containing formulation of RiVax and tested it in rhesus macaques. After three injections, the animals developed antibodies that completely protected them from a lethal dose of aerosolized RT. These antibodies neutralized RT and competed to varying degrees with a panel of neutralizing and nonneutralizing mouse monoclonal antibodies known to recognize specific epitopes on native RTA. The resulting antibody competition profile could represent an immunologic signature of protection. Importantly, the same signature was observed using sera from RiVax-immunized humans.


Asunto(s)
Anticuerpos Neutralizantes/química , Epítopos/química , Ricina/química , Vacunas/química , Aerosoles , Animales , Anticuerpos Monoclonales/química , Ensayo de Inmunoadsorción Enzimática , Células Epiteliales/química , Humanos , Inmunoglobulina G/química , Pulmón/patología , Macaca mulatta , Ratones , Conformación Molecular , Temperatura
7.
Viruses ; 14(1)2022 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-35062281

RESUMEN

In recent months, several SARS-CoV-2 variants have emerged that enhance transmissibility and escape host humoral immunity. Hence, the tracking of viral evolutionary trajectories is clearly of great importance. Little is known about SARS-CoV-2 evolution in nonhuman primate models used to test vaccines and therapies and to model human disease. Viral RNA was sequenced from rectal swabs from Chlorocebus aethiops (African green monkeys) after experimental respiratory SARS-CoV-2 infection. Two distinct patterns of viral evolution were identified that were shared between all collected samples. First, mutations in the furin cleavage site that were initially present in the virus as a consequence of VeroE6 cell culture adaptation were not detected in viral RNA recovered in rectal swabs, confirming the necessity of this motif for viral infection in vivo. Three amino acid changes were also identified; ORF 1a S2103F, and spike D215G and H655Y, which were detected in rectal swabs from all sampled animals. These findings are demonstrative of intra-host SARS-CoV-2 evolution and may identify a host-adapted variant of SARS-CoV-2 that would be useful in future primate models involving SARS-CoV-2 infection.


Asunto(s)
COVID-19/virología , SARS-CoV-2/genética , Animales , Chlorocebus aethiops , Modelos Animales de Enfermedad , Evolución Molecular , Mutación , Poliproteínas/genética , ARN Viral/genética , Recto/virología , Glicoproteína de la Espiga del Coronavirus/genética , Células Vero , Proteínas Virales/genética
8.
Viral Immunol ; 35(3): 192-199, 2022 04.
Artículo en Inglés | MEDLINE | ID: mdl-35333631

RESUMEN

Chikungunya (CHIKV) is an emerging worldwide viral threat. The immune response to infection can lead to protection and convalescence or result in long-term sequelae such as arthritis. Early innate immune events during acute infection have been characterized for some cell types, but more must be elucidated with respect to cellular responses of monocytes and other myeloid lineage cells. In addition to their roles in protection and inflammation resolution, monocytes and macrophages are sites for viral replication and may also act as viral reservoirs. These cells are also found in joints postinfection, possibly playing a role in long-term CHIKV-induced pathology. We examined kinetic and phenotypic changes in myeloid lineage cells, including monocytes, in cynomolgus macaques early after experimental infection with CHIKV. We found increased proliferation of monocytes and decreased proliferation of myeloid dendritic cells early during infection, with an accompanying decrease in absolute numbers of both cell types, as well as a simultaneous increase in plasmacytoid dendritic cell number. An increase in CD16 and CD14 was seen along with a decrease in monocyte Human Leukocyte Antigen-DR isotype expression within 3 days of infection, potentially indicating monocyte deactivation. A transient decrease in T cells, B cells, and natural killer cells correlated with lymphocytopenia observed during human infections with CHIKV. CD4+ T cell proliferation decreased in blood, indicating relocation of cells to effector sites. These data indicate CHIKV influences proliferation rates and kinetics of myeloid lineage cells early during infection and may prove useful in development of therapeutics and evaluation of infection-induced pathogenesis.


Asunto(s)
Fiebre Chikungunya , Animales , Linaje de la Célula , Fiebre Chikungunya/complicaciones , Cinética , Macaca , Monocitos
9.
J Aerosol Med Pulm Drug Deliv ; 35(1): 50-56, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34619040

RESUMEN

Background: Bacillus Calmette-Guérin (BCG) is a vaccine used to protect against tuberculosis primarily in infants to stop early infection in areas of the world where the disease is endemic. Normally administered as a percutaneous injection, BCG is a live significantly attenuated bacteria that is now being investigated for its potential within an inhalable vaccine formulation. This study investigates the feasibility and performance of two jet and two vibrating mesh nebulizers aerosolizing BCG and the resulting particle characteristics and residual viability of the bacteria postaerosolization. Methods: A jet nebulizer (Collison), outfitted either with a 3- or 6-jet head, was compared with two clinical nebulizers, the vibrating mesh Omron MicroAir and Aerogen Solo devices. Particle characteristics, including aerodynamic particle sizing, was performed on all devices within a common aerosol chamber configuration and comparable BCG innocula concentrations. Integrated aerosol samples were collected for each generator and assayed for bacterial viability using conventional microbiological technique. Results: A batch lot of BCG (Danish) was grown to titer and used in all generator assessments. Aerosol particles within the respirable range were generated from all nebulizers at four different concentrations of BCG. The jet nebulizers produced a uniformly smaller particle size than the vibrating mesh devices, although particle concentrations by mass were similar across all devices tested with the exception of the Aerogen Solo, which resulted in a low concentration of BCG aerosols. Conclusions: The resulting measured viable BCG aerosol concentration fraction produced by each device approximated one another; however, a measurable decrease of efficiency and overall viability reduction in the jet nebulizer was observed in higher BCG inoculum starting concentrations, whereas the vibrating mesh nebulizer returned a remarkably stable viable aerosol fraction irrespective of inoculum concentration.


Asunto(s)
Vacuna BCG , Mallas Quirúrgicas , Administración por Inhalación , Aerosoles , Albuterol , Broncodilatadores , Sistemas de Liberación de Medicamentos , Diseño de Equipo , Humanos , Nebulizadores y Vaporizadores , Tamaño de la Partícula
10.
J Ophthalmic Inflamm Infect ; 8(1): 19, 2018 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-30357549

RESUMEN

BACKGROUND: A multipurpose contact lens cleaning solution (MPS) containing novel active ingredients under development was compared to two commercially available MPS solutions for effectiveness against Acanthamoeba isolates. METHODS: The Acanthamoeba isolate A. castellanii was propagated for trophozoite or cyst-containing cultures for the purpose of assessment of effectiveness of each MPS. An alamar blue-based cellular respiration assay was used to assess effectiveness against trophozoites; Trypan blue hemocytometer-based microscopic counts measured cysticidal effects. To assess the general antimicrobial potency of each solution as controls for the anti-amoebic assays, comparative bactericidal effectiveness using Serratia marcenses was also performed. RESULTS: Minimal effectiveness against either Acanthamoeba form was observed from either commercial MPS. In contrast, the novel MPS achieved complete kill within 1 h contact time for both Acanthamoeba trophozoite and cysts. Each commercial MPS required 6 h contact time to achieve a two to three log reduction in S. marcenses. In contrast, the experimental MPS achieved disinfection in 60 min contact time, and complete kill (< 1 CFU) at 90 min. CONCLUSIONS: Results suggest that the inclusion of a novel ingredient combination within the MPS under development clearly is required and is ideal for rapid and effective killing of Acanthamoeba species in the context of contact lens disinfection systems. The representative commercially available MPS used in this testing provided minimal effectiveness against the protozoa regardless of contact time. In addition, comparative results with the bacterial agent in the control study show distinct differences in the speed to disinfection with the novel MPS. Future MPS development should consider inclusion of novel chemical entities that are effective against Acanthamoeba species to speed disinfection and further reduce the exposure potential of users of contact lenses and cleaning systems.

11.
PLoS Negl Trop Dis ; 9(5): e0003797, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-26020513

RESUMEN

Venezuelan equine encephalitis virus (VEEV) is an arbovirus endemic to the Americas that is responsible for severe, sometimes fatal, disease in humans and horses. We previously described an IRES-based VEE vaccine candidate based up the IE serotype that offers complete protection against a lethal subtype IE VEEV challenge in mice. Here we demonstrate the IRES-based vaccine's ability to protect against febrile disease in cynomolgus macaques. Vaccination was well tolerated and elicited robust neutralizing antibody titers noticed as early as day 14. Moreover, complete protection from disease characterized by absence of viremia and characteristic fever following aerosolized IE VEEV challenge was observed in all vaccinees compared to control animals, which developed clinical disease. Together, these results highlight the safety and efficacy of IRES-based VEEV vaccine to protect against an endemic, pathogenic VEEV IE serotype.


Asunto(s)
Anticuerpos Antivirales/sangre , Virus de la Encefalitis Equina Venezolana/inmunología , Encefalomielitis Equina Venezolana/prevención & control , Enfermedades de los Caballos/prevención & control , Vacunación , Vacunas Virales/inmunología , Aerosoles , Animales , Anticuerpos Neutralizantes/sangre , Chlorocebus aethiops , Modelos Animales de Enfermedad , Encefalomielitis Equina Venezolana/inmunología , Femenino , Enfermedades de los Caballos/inmunología , Caballos , Humanos , Sitios Internos de Entrada al Ribosoma/inmunología , Macaca fascicularis , Masculino , Sustancias Protectoras , Distribución Aleatoria , Vacunas Atenuadas/inmunología , Células Vero , Viremia
12.
J Virol Methods ; 187(2): 333-7, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23142251

RESUMEN

Viral aerosols can have a major impact on public health and on the dynamics of infection. Once aerosolized, viruses are subjected to various stress factors and their integrity and potential of infectivity can be altered. Empirical characterization is needed in order to predict more accurately the fate of these bioaerosols both for short term and long term suspension in the air. Here the susceptibility to aerosolization of the monkeypox virus (MPXV), associated with emerging zoonotic diseases, was studied using a 10.7 L rotating chamber. This chamber was built to fit inside a Class three biological safety cabinet, specifically for studying airborne biosafety level three (BSL3) microorganisms. Airborne viruses were detected by culture and quantitative polymerase chain reaction (qPCR) after up to 90 h of aging. Viral concentrations detected dropped by two logs for culture analysis and by one log for qPCR analysis within the first 18 h of aging; viral concentrations were stable between 18 and 90 h, suggesting a potential for the MPXV to retain infectivity in aerosols for more than 90 h. The rotating chamber used in this study maintained viral particles airborne successfully for prolonged periods and could be used to study the susceptibility of other BSL3 microorganisms.


Asunto(s)
Aerosoles , Viabilidad Microbiana , Monkeypox virus/fisiología , Reacción en Cadena en Tiempo Real de la Polimerasa , Factores de Tiempo , Carga Viral
13.
Antiviral Res ; 93(1): 204-8, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22146565

RESUMEN

Smallpox is considered a biological threat based upon the possibility of deliberate reintroduction into the population, creating an urgent need for effective antivirals. The antiviral drug cidofovir (Cr) has shown to be effective against poxviruses, although route-specific nephrotoxicity has hampered its development for emergency post-exposure prophylaxis (PEP). In this study, we use a micronized dry powder formulation of pharmaceutical-grade Cr (NanoFOVIRTM; Nf) to treat rabbits exposed to aerosolized rabbitpox virus (RPXV) to further evaluate the effectiveness of direct drug delivery to the lung. Naïve rabbits were infected with RPXV by aerosol; three subsets received aerosolized Nf at 0.5, 1.0 or 1.75mg/kg daily for 3days post-exposure, positive and negative control groups received intravenous (IV) Cr treatments and no treatment, respectively. Nf groups showed an antiviral-dose associated survival of 50% (0.5mg/kg), 80% (1.0mg/kg) and 100% (1.75mg/kg). All animals (100%) from the IV-Cr treatment group and none (0%) from the untreated controls survived. Nf (1.75) protected rabbits from RPX at approximately 10% of the equivalent IV-Cr dose. A dose-related effect was observed in clinical development of RPX disease in Nf groups. Significant reduction of RPX-induced pathological changes was observed in Nf (1.75) and IV-Cr groups. Results suggest that Nf may be a viable antiviral for emergency post-exposure prophylaxis and should be evaluated in other models of poxviral disease.


Asunto(s)
Antivirales/administración & dosificación , Citosina/análogos & derivados , Organofosfonatos/administración & dosificación , Profilaxis Posexposición , Virus Vaccinia , Vaccinia/prevención & control , Administración por Inhalación , Animales , Línea Celular , Cidofovir , Citosina/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Pulmón/patología , Pulmón/virología , Masculino , Conejos , Vaccinia/mortalidad , Vaccinia/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA